Mediastinal Lymphadenopathy
Conditions
Brief summary
The goal of this clinical trial is to clear the diagnostic yield and safety of endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy (TBMC) via a tunnel. The main questions it aims to answer are: Does EBUS-TBMC via a tunnel have a superior diagnostic yield to EBUS-transbronchial needle aspiration (TBNA)? When EBUS-TBMC via a tunnel could be performed as a first-line diagnostic tool in patients with mediastinal and/or hilar lymphadenopathy? Researchers will compare EBUS-TBMC via a tunnel to EBUS-TBNA to see if EBUS-TBMC via a tunnel has a superior of diagnostic yield with a well-tolerance. Participants will: Recieve EBUS-TBMC via a tunnel and EBUS-TBNA in a predefined sequence. Recieve chest CT examination and follow-up for 7 days after procedure.
Interventions
PROCEDUREEBUS-TBNA
Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.
PROCEDUREEBUS-TBMC via a tunnel
Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
Sponsors
China-Japan Friendship Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with at least one mediastinal and/or hilar lymphadenopathy (≥1cm in the short axis) in the absence of a known or suspected primary lung cancer, requiring diagnostic bronchoscopy. * The selected patients should complete the routine examination of EBUS-TBNA/EBUS-TBMC via a tunnel before operation, such as blood routine examination, coagulation function, electrocardiogram, chest CT, etc. * There was no contraindication of puncture and cryobiopsy. * Fully informed of the purpose and method of the study, agreed to participate in the study, and signed the informed consent form.
Exclusion criteria
* The lesion is a mediastinal cyst or abscess. * The patient is allergic to lidocaine and midazolam. * The site to be biopsied has a high risk of bleeding detected by Doppler and/or contrast CT such as bronchial artery penetration or suspected lung metastasis of renal cancer. * Unstable angina pectoris, congestive heart failure, severe bronchial asthma * The patient did not agree to participate in this study * Participation in other studies within three months without withdrawal or termination will affect the observation of this study * The researcher believes that there is any person who is not suitable for the selection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic yield | 6 months after the biopsy | The proportion of all individuals undergoing the diagnostic procedure under evaluation in whom a specific diagnosis was established. All the final diagnosis in this trial were established by the treating clinician and verified by an independent diagnosis verification panel which included three pulmonary and critical care medicine physicians, one radiologist, and one pathologist. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic sensitivity | 6 months after biopsy. | The proportion of individuals who truly had the disease and tested positive. |
| Incidence rate of adverse events | 7 days after the biopsy | Symptoms and signs |
| Size of specimen | during the procedure | measurement |
| Specimen quality | during the procedure | questionnaire |
Countries
China
Outcome results
None listed